KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Invested Capital (2016 - 2025)

Historic Invested Capital for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $355.2 million.

  • Alnylam Pharmaceuticals' Invested Capital rose 99783.64% to $355.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $355.2 million, marking a year-over-year increase of 99783.64%. This contributed to the annual value of $160.9 million for FY2024, which is 17291.75% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Invested Capital stood at $355.2 million for Q3 2025, which was up 99783.64% from $371.4 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Invested Capital high stood at $1.3 billion for Q2 2021, and its period low was -$408.1 million during Q2 2023.
  • In the last 5 years, Alnylam Pharmaceuticals' Invested Capital had a median value of $160.9 million in 2024 and averaged $339.0 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Invested Capital tumbled by 14780.38% in 2023, and later surged by 1220925.99% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Invested Capital (Quarter) stood at $1.3 billion in 2021, then plummeted by 112.52% to -$158.2 million in 2022, then tumbled by 39.45% to -$220.6 million in 2023, then surged by 172.92% to $160.9 million in 2024, then surged by 120.77% to $355.2 million in 2025.
  • Its Invested Capital stands at $355.2 million for Q3 2025, versus $371.4 million for Q2 2025 and $233.5 million for Q1 2025.